NEW
BRUNSWICK, NEW JERSEY—
Johnson & Johnson has begun clinical trials for an Ebola
vaccine in Sierra Leone.
The vaccine regimen is part of a new study being conducted
in that nation's Kambia district, where some of the country's most recent Ebola
cases have been reported.
More than 11,000 people have died from the Ebola virus since
the latest outbreak emerged in late 2013, nearly all of them in West Africa in
and around Sierra Leone.
There is currently no licensed vaccine, treatment or cure
for Ebola.
The Johnson & Johnson study, in development at
subsidiary Janssen Pharmaceutical Cos., will evaluate safety and immune
response within Sierra Leone's general population.
The company said Friday that the first volunteers have
received the initial dose.
Johnson & Johnson, based in New Brunswick, New Jersey,
said that there are separate studies being conducted in the U.S., Europe and
Africa as part of the accelerated development plan to prevent
0 comments:
Post a Comment
Please insert your comments here